<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">sechenov</journal-id><journal-title-group><journal-title xml:lang="en">Sechenov Medical Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Сеченовский вестник</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2218-7332</issn><issn pub-type="epub">2658-3348</issn><publisher><publisher-name>Сеченовский Университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47093/2218-7332.2022.13.4.33-44</article-id><article-id custom-type="elpub" pub-id-type="custom">sechenov-883</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>COVID-19</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>COVID-19</subject></subj-group></article-categories><title-group><article-title>Angiopoietin-1 as a marker of endothelial dysfunction and a risk factor for acute kidney injury in patients with COVID-19: retrospective cohort study</article-title><trans-title-group xml:lang="ru"><trans-title>Ангиопоэтин-1 как маркер эндотелиальной дисфункции и фактор риска острого почечного повреждения у больных COVID-19: ретроспективное когортное исследование</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1826-0519</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щепалина</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Schepalina</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Щепалина Анастасия Александровна, аспирант кафедры внутренних, профессиональных болезней и ревматологии</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991</p><p>Тел.: +7 (989) 836-21-31</p></bio><bio xml:lang="en"><p>Anastasia A. Schepalina, postgraduate student, Department of Internal Diseases, Occupational Diseases and Rheumatology</p><p>8/2, Trubetskaya str., Moscow, 119991</p><p>Тел.: +7 (989) 836-21-31</p></bio><email xlink:type="simple">anastasia.schepalina@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2128-8560</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чеботарева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chebotareva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чеботарева Наталья Викторовна, д-р мед. наук, врач-нефролог, профессор кафедры внутренних, профессиональных болезней и ревматологии</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Natalia V. Chebotareva, Dr. of Sci. (Medicine), nephrologist, Professor, Department of Internal Diseases, Occupational Diseases and Rheumatology</p><p>8/2, Trubetskaya str., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4307-8882</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Акулкина</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Akulkina</surname><given-names>L. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Акулкина Лариса Анатольевна, врач-пульмонолог, ассистент кафедры внутренних, профессиональных болезней и ревматологии</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Larisa A. Akulkina, pulmonologist, Assistant Professor, Department of Internal Diseases, Occupational Diseases and Rheumatology</p><p>8/2, Trubetskaya str., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0023-2701</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бровко</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Brovko</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бровко Михаил Юрьевич, канд. мед. наук, врач-пульмонолог, доцент кафедры внутренних, профессиональных болезней и ревматологии</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Mikhail Yu. Brovko, Cand. of Sci. (Medicine), pulmonologist, Associate Professor, Department of Internal Diseases, Occupational Diseases and Rheumatology</p><p>8/2, Trubetskaya str., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8785-7968</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шоломова</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Sholomova</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шоломова Виктория Игоревна, канд. мед. наук, врач-пульмонолог, ассистент кафедры внутренних, профессиональных болезней и ревматологии</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Viktoriya I. Sholomova, Cand. of Sci. (Medicine), pulmonologist, Assistant Professor, Department of Internal Diseases, Occupational Diseases and Rheumatology</p><p>8/2, Trubetskaya str., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4366-2832</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Потапов</surname><given-names>П. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Potapov</surname><given-names>P. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Потапов Павел Петрович, врач-терапевт Университетской клинической больницы № 3; аспирант кафедры внутренних болезней факультета фундаментальной медицины</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991</p><p>Ленинские горы, д. 1, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Pavel P. Potapov, physician, University Clinical Hospital No.3; postgraduate student, Department of Internal Diseases, Faculty of Basic Medicine</p><p>8/2, Trubetskaya str., Moscow, 119991</p><p>1, Leninskie Gory, Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4250-9468</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Валиулина</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Valiulina</surname><given-names>D. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Валиулина Динар Сандаровна, врач лабораторной диагностики, биолог Централизованной лабораторно-диагностической службы</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Dinar S. Valiulina, laboratory-doctor, biologist, Central laboratory and diagnostic service</p><p>8/2, Trubetskaya str., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7232-4640</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моисеев</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Moiseev</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Моисеев Сергей Валентинович, член.-корр. РАН, д-р мед. наук, профессор, зав. кафедрой внутренних, профессиональных болезней и ревматологии, директор Клиники ревматологии, нефрологии и профпатологии им. Е.М. Тареева Университетской клинической больницы № 3; профессор кафедры внутренних болезней факультета фундаментальной медицины</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991</p><p>Ленинские горы, д. 1, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Sergey V. Moiseev, Corresponding Member of RAS, Dr. of Sci. (Medicine), Professor, Head of the Department of Internal Diseases, Occupational Diseases and Rheumatology, Director of E.M. Tareev Clinic of Rheumatology, Nephrology and Occupational Diseases, University Clinical Hospital No.3; Professor, Department of Internal Diseases, Faculty of Basic Medicine</p><p>8/2, Trubetskaya str., Moscow, 119991</p><p>1, Leninskie Gory, Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет); ФГБОУ ВО «Московский государственный университет имени М.В. Ломоносова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University (Sechenov University); Lomonosov Moscow State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>28</day><month>11</month><year>2022</year></pub-date><volume>13</volume><issue>4</issue><fpage>33</fpage><lpage>44</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Schepalina A.A., Chebotareva N.V., Akulkina L.A., Brovko M.Y., Sholomova V.I., Potapov P.P., Valiulina D.S., Moiseev S.V., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Щепалина А.А., Чеботарева Н.В., Акулкина Л.А., Бровко М.Ю., Шоломова В.И., Потапов П.П., Валиулина Д.С., Моисеев С.В.</copyright-holder><copyright-holder xml:lang="en">Schepalina A.A., Chebotareva N.V., Akulkina L.A., Brovko M.Y., Sholomova V.I., Potapov P.P., Valiulina D.S., Moiseev S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sechenovmedj.com/jour/article/view/883">https://www.sechenovmedj.com/jour/article/view/883</self-uri><abstract><p>Recently, data have been published on the leading role of endothelial dysfunction in the development of severe COVID-19, including acute renal failure (AKI) and poor prognosis in this group of patients.</p><sec><title>Aim</title><p>Aim. To define the role of angiopoetin-1(Ang-1) as a marker of endothelial dysfunction in development of AKI in patients, hospitalized with COVID-19.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. 76 patients with confirmed coronavirus infection were included in the study. AKI was diagnosed according to KDIGO 2012 criteria in 44 patients (group 1), 32 patients without sings of kidney disfunction were in group 2. Beside standard clinical and laboratory markers on admission we evaluated serum Ang-1 level with ELISA. We used regression analysis for AKI risk factors evaluation, we calculated odds ratio (OR) and 95% confidence intervals (CI). We used Cox regression for evaluation of risk of death.</p></sec><sec><title>Results</title><p>Results. The serum level of angiopoietin-1 was significantly higher in patients with COVID-19 with AKI: 1.8 (1.5; 2.1) ng/ml vs 1.58 (1.29; 1.7) ng/ml in group 2, р &lt; 0.01. In deceased patients, the level of Ang-1 at admission was significantly higher than in patients who was discharged: 1.91 (1.71; 2.32) ng/ml vs 1.58 (1.34; 1.67) ng/ml, respectively, p = 0.0001. In unifactorial regression analysis we confirmed, that increase of serum Ang-1 level &gt;1.66 ng/ml on admission is the risk factor for AKI development in patients with COVID-19 (OR 5.7, 95% CI 1.7–19.1, р &lt; 0.01). In Cox regression development of AKI increased the absolute risk of death: Hazard ratio = 5.159 (95% CI 1.839–14.469), p = 0.002.</p></sec><sec><title>Conclusion</title><p>Conclusion. The high serum level of Ang-1 in patients with COVID-19 at hospital admission is the marker of systemic endothelial dysfunction and the risk factor for AKI and poor prognosis.</p></sec></abstract><trans-abstract xml:lang="ru"><p>В последнее время опубликованы данные о ведущем значении эндотелиальной дисфункции в развитии тяжелого течения COVID-19, в том числе острого повреждения почек (ОПП) и неблагоприятного прогноза в этой группе больных.</p><sec><title>Цель</title><p>Цель. Определить роль ангиопоэтина-1 (Ang-1), маркера эндотелиальной дисфункции, в развитии ОПП у госпитализированных больных COVID-19.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование были включены 76 пациентов с подтвержденной коронавирусной инфекцией. ОПП было диагностировано согласно критериям KDIGO 2012 г. у 44 пациентов (группа 1), 32 пациента без признаков дисфункции почек вошли в группу 2. Помимо стандартных клинико-лабораторных показателей, при поступлении определяли уровень Ang-1 в сыворотке крови иммуноферментным анализом. Для оценки факторов риска ОПП был применен логистический регрессионный анализ, вычислены отношения шансов и 95% доверительные интервалы (ДИ). Для оценки риска летального исхода построена регрессионная модель Кокса.</p></sec><sec><title>Результаты</title><p>Результаты. Уровень Ang-1 в сыворотке крови был статистически значимо выше у пациентов с ОПП: 1,8 (1,5; 2,1) нг/мл против 1,58 (1,29; 1,7) нг/мл в группе 2, р &lt; 0,01. У умерших пациентов уровень Ang-1 при поступлении был статистически значимо более высоким, чем у выживших: 1,91 (1,71; 2,32) нг/мл против 1,58 (1,34; 1,67) нг/мл соответственно, p = 0,0001. По данным монофакторного логистического регрессионного анализа установлено, что повышение Ang-1 &gt; 1,66 нг/мл в сыворотке крови при поступлении является фактором риска развития ОПП у пациентов с COVID-19 (отношение шансов 5,7; 95% ДИ 1,7–19,1; р &lt; 0,01). В регрессионной модели Кокса присоединение ОПП повышало абсолютный риск летального исхода: Hazard ratio = 5,159 (95% ДИ 1,839–14,469), p = 0,002.</p></sec><sec><title>Заключение</title><p>Заключение. Обнаружение высокого уровня Ang-1 в сыворотке крови больных COVID-19 при поступлении в стационар является отражением системной эндотелиальной дисфункции, фактором риска ОПП и неблагоприятного прогноза.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>эндотелий</kwd><kwd>фибрилляция предсердий</kwd><kwd>сердечная недостаточность</kwd><kwd>артериальная гипертензия</kwd><kwd>С-реактивный белок</kwd><kwd>ROC-кривая</kwd></kwd-group><kwd-group xml:lang="en"><kwd>endothelium</kwd><kwd>atrial fibrillation</kwd><kwd>heart failure</kwd><kwd>arterial hypertension</kwd><kwd>C-reactive protein</kwd><kwd>ROC curve</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Авторы выражают благодарность руководителю Централизованной лабораторно-диагностической службы Сеченовского Университета Н.М. Кашакановой и заведующей межклинической биологической лабораторией Централизованной лабораторно-диагностической службы Сеченовского Университета А.Ю. Федоровой за помощь в проведении иммуноферментного анализа для определения концентрации ангиопоэтина-1 в сыворотке крови.</funding-statement><funding-statement xml:lang="en">Authors would like to thank Natalia M. Kashakanova, Head of the Central laboratory and diagnostic service of Sechenov University, and Alina Yu. Fedorova, Head of interclinical biochemical department of the Central laboratory and diagnostic service of Sechenov University for assistance in measuring the concentration of angiopoetin-1 with the enzyme-linked immunosorbent assay.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021 Mar; 19(3): 141–154. https://doi.org/10.1038/s41579-020-00459-7. Epub 2020 Oct 6. Erratum in: Nat Rev Microbiol. 2022 May; 20(5): 315. PMID: 33024307.</mixed-citation><mixed-citation xml:lang="en">Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021 Mar; 19(3): 141–154. https://doi.org/10.1038/s41579-020-00459-7. Epub 2020 Oct 6. Erratum in: Nat Rev Microbiol. 2022 May; 20(5): 315. PMID: 33024307.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Guan W.J., Ni Z.Y., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30; 382(18): 1708–1720. https://doi.org/10.1056/NEJMoa2002032. Epub 2020 Feb 28. PMID: 32109013.</mixed-citation><mixed-citation xml:lang="en">Guan W.J., Ni Z.Y., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30; 382(18): 1708–1720. https://doi.org/10.1056/NEJMoa2002032. Epub 2020 Feb 28. PMID: 32109013.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Prasad N., Novak J.E., Patel M.R. Kidney diseases associated with Parvovirus B19, Hanta, Ebola, and Dengue virus infection: A brief review. Adv Chronic Kidney Dis. 2019 May; 26(3): 207–219. https://doi.org/10.1053/j.ackd.2019.01.006. PMID: 31202393.</mixed-citation><mixed-citation xml:lang="en">Prasad N., Novak J.E., Patel M.R. Kidney diseases associated with Parvovirus B19, Hanta, Ebola, and Dengue virus infection: A brief review. Adv Chronic Kidney Dis. 2019 May; 26(3): 207–219. https://doi.org/10.1053/j.ackd.2019.01.006. PMID: 31202393.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hirsch J.S., Ng J.H., Ross D.W., et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020 Jul; 98(1): 209–218. https://doi.org/10.1016/j.kint.2020.05.006. Epub 2020 May 16. PMID: 32416116.</mixed-citation><mixed-citation xml:lang="en">Hirsch J.S., Ng J.H., Ross D.W., et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020 Jul; 98(1): 209–218. https://doi.org/10.1016/j.kint.2020.05.006. Epub 2020 May 16. PMID: 32416116.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Diao B., Wang C., Wang R., et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2021 May 4; 12(1): 2506. https://doi.org/10.1038/s41467-021-22781-1. PMID: 33947851.</mixed-citation><mixed-citation xml:lang="en">Diao B., Wang C., Wang R., et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2021 May 4; 12(1): 2506. https://doi.org/10.1038/s41467-021-22781-1. PMID: 33947851.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ali H., Daoud A., Mohamed M.M., et al. Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis. Ren Fail. 2020 Nov; 42(1): 393–397. https://doi.org/10.1080/0886022X.2020.1756323. PMID: 32340507.</mixed-citation><mixed-citation xml:lang="en">Ali H., Daoud A., Mohamed M.M., et al. Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis. Ren Fail. 2020 Nov; 42(1): 393–397. https://doi.org/10.1080/0886022X.2020.1756323. PMID: 32340507.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lin L., Wang X., Ren J., et al. Risk factors and prognosis for COVID-19-induced acute kidney injury: a meta-analysis. BMJ Open. 2020 Nov 10; 10(11): e042573. https://doi.org/10.1136/bmjopen-2020-042573. PMID: 33172950.</mixed-citation><mixed-citation xml:lang="en">Lin L., Wang X., Ren J., et al. Risk factors and prognosis for COVID-19-induced acute kidney injury: a meta-analysis. BMJ Open. 2020 Nov 10; 10(11): e042573. https://doi.org/10.1136/bmjopen-2020-042573. PMID: 33172950.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wang D., Hu B., Hu C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Mar 17; 323(11): 1061–1069. https://doi.org/10.1001/jama.2020.1585. Erratum in: JAMA. 2021 Mar 16; 325(11): 1113. PMID: 32031570.</mixed-citation><mixed-citation xml:lang="en">Wang D., Hu B., Hu C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Mar 17; 323(11): 1061–1069. https://doi.org/10.1001/jama.2020.1585. Erratum in: JAMA. 2021 Mar 16; 325(11): 1113. PMID: 32031570.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L., Li X., Chen H., et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol. 2020; 51(5): 343–348. https://doi.org/10.1159/000507471. Epub 2020 Mar 31. PMID: 32229732.</mixed-citation><mixed-citation xml:lang="en">Wang L., Li X., Chen H., et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol. 2020; 51(5): 343–348. https://doi.org/10.1159/000507471. Epub 2020 Mar 31. PMID: 32229732.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Su H., Yang M., Wan C., et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020 Jul; 98(1): 219–227. Epub 2020 Apr 9. https://doi.org/10.1016/j.kint.2020.04.003. PMID: 32327202.</mixed-citation><mixed-citation xml:lang="en">Su H., Yang M., Wan C., et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020 Jul; 98(1): 219–227. Epub 2020 Apr 9. https://doi.org/10.1016/j.kint.2020.04.003. PMID: 32327202.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Li X.Q., Liu H., Meng Y., et al. Critical roles of cytokine storm and secondary bacterial infection in acute kidney injury development in COVID-19: A multi-center retrospective cohort study. J Med Virol. 2021 Dec; 93(12): 6641–6652. https://doi.org/10.1002/jmv.27234. Epub 2021 Aug 14. PMID: 34314040.</mixed-citation><mixed-citation xml:lang="en">Li X.Q., Liu H., Meng Y., et al. Critical roles of cytokine storm and secondary bacterial infection in acute kidney injury development in COVID-19: A multi-center retrospective cohort study. J Med Virol. 2021 Dec; 93(12): 6641–6652. https://doi.org/10.1002/jmv.27234. Epub 2021 Aug 14. PMID: 34314040.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">van der Heijden M., Pickkers P., van Nieuw Amerongen G.P., et al. Circulating angiopoietin-2 levels in the course of septic shock: relation with fluid balance, pulmonary dysfunction and mortality. Intensive Care Med. 2009 Sep; 35(9): 1567–1574. Epub 2009 Jun 24. https://doi.org/10.1007/s00134-009-1560-y. PMID: 19551369.</mixed-citation><mixed-citation xml:lang="en">van der Heijden M., Pickkers P., van Nieuw Amerongen G.P., et al. Circulating angiopoietin-2 levels in the course of septic shock: relation with fluid balance, pulmonary dysfunction and mortality. Intensive Care Med. 2009 Sep; 35(9): 1567–1574. Epub 2009 Jun 24. https://doi.org/10.1007/s00134-009-1560-y. PMID: 19551369.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997 Jul 4; 277(5322): 55–60. https://doi.org/10.1126/science.277.5322.55. PMID: 9204896.</mixed-citation><mixed-citation xml:lang="en">Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997 Jul 4; 277(5322): 55–60. https://doi.org/10.1126/science.277.5322.55. PMID: 9204896.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Butler A.E., Al-Qaissi A., Sathyapalan T., Atkin S.L. Angiopoietin-1: an early biomarker of diabetic nephropathy? J Transl Med. 2021 Oct 13; 19(1): 427. https://doi.org/10.1186/s12967-021-03105-9. PMID: 34645474.</mixed-citation><mixed-citation xml:lang="en">Butler A.E., Al-Qaissi A., Sathyapalan T., Atkin S.L. Angiopoietin-1: an early biomarker of diabetic nephropathy? J Transl Med. 2021 Oct 13; 19(1): 427. https://doi.org/10.1186/s12967-021-03105-9. PMID: 34645474.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hall A., Busse L.W., Ostermann M. Angiotensin in critical care. Crit Care. 2018 Mar 20; 22(1): 69. https://doi.org/10.1186/s13054-018-1995-z. PMID: 29558991.</mixed-citation><mixed-citation xml:lang="en">Hall A., Busse L.W., Ostermann M. Angiotensin in critical care. Crit Care. 2018 Mar 20; 22(1): 69. https://doi.org/10.1186/s13054-018-1995-z. PMID: 29558991.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ricciuto D.R., dos Santos C.C., Hawkes M., et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med. 2011 Apr; 39(4): 702–710. https://doi.org/10.1097/CCM.0b013e318206d285. PMID: 21242795.</mixed-citation><mixed-citation xml:lang="en">Ricciuto D.R., dos Santos C.C., Hawkes M., et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med. 2011 Apr; 39(4): 702–710. https://doi.org/10.1097/CCM.0b013e318206d285. PMID: 21242795.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Henry B.M., de Oliveira M.H.S., Cheruiyot I., et al. Circulating level of Angiopoietin-2 is associated with acute kidney injury in coronavirus disease 2019 (COVID-19). Angiogenesis. 2021 Aug; 24(3): 403–406. Epub 2021 Mar 23. https://doi.org/10.1007/s10456-021-09782-w. PMID: 33755876.</mixed-citation><mixed-citation xml:lang="en">Henry B.M., de Oliveira M.H.S., Cheruiyot I., et al. Circulating level of Angiopoietin-2 is associated with acute kidney injury in coronavirus disease 2019 (COVID-19). Angiogenesis. 2021 Aug; 24(3): 403–406. Epub 2021 Mar 23. https://doi.org/10.1007/s10456-021-09782-w. PMID: 33755876.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Щепалина А.А., Чеботарева Н.В., Китбалян А.А. и др. Факторы риска повреждения почек у пациентов с острой коронавирусной инфекцией COVID-19. Терапевтический архив. 2022; 94(6): 743–747. https://doi.org/10.26442/00403660.2022.06.201568. PMID: 36286851.</mixed-citation><mixed-citation xml:lang="en">Schepalina A.A., Chebotareva N.V., Kitbalian A.A., et al. Risk factors of kidney injury in patients with COVID-19. Ter Arkh. 2022 Aug 4; 94(6): 743–747 (In Russian). https://doi.org/10.26442/00403660.2022.06.201568. PMID: 36286851.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Shah S.J., Barish P.N., Prasad P.A., et al. Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: A retrospective cohort study of patients with and without COVID-19. EClinicalMedicine. 2020 Oct; 27: 100518. Epub 2020 Aug 26. https://doi.org/10.1016/j.eclinm.2020.100518. PMID: 32864588.</mixed-citation><mixed-citation xml:lang="en">Shah S.J., Barish P.N., Prasad P.A., et al. Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: A retrospective cohort study of patients with and without COVID-19. EClinicalMedicine. 2020 Oct; 27: 100518. Epub 2020 Aug 26. https://doi.org/10.1016/j.eclinm.2020.100518. PMID: 32864588.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Chan L., Chaudhary K., Saha A., et al. AKI in hospitalized patients with COVID-19. J Am Soc Nephrol. 2021 Jan; 32(1): 151–160. Epub 2020 Sep 3. https://doi.org/10.1681/ASN.2020050615. PMID: 32883700.</mixed-citation><mixed-citation xml:lang="en">Chan L., Chaudhary K., Saha A., et al. AKI in hospitalized patients with COVID-19. J Am Soc Nephrol. 2021 Jan; 32(1): 151– 160. Epub 2020 Sep 3. https://doi.org/10.1681/ASN.2020050615. PMID: 32883700.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Feng X., Li P., Ma L., et al. Clinical characteristics and shortterm outcomes of severe patients with COVID-19 in Wuhan, China. Front Med (Lausanne). 2020 Aug 6; 7: 491. https://doi.org/10.3389/fmed.2020.00491. PMID: 32850926.</mixed-citation><mixed-citation xml:lang="en">Feng X., Li P., Ma L., et al. Clinical characteristics and shortterm outcomes of severe patients with COVID-19 in Wuhan, China. Front Med (Lausanne). 2020 Aug 6; 7: 491. https://doi.org/10.3389/fmed.2020.00491. PMID: 32850926.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sullivan M.K., Lees J.S., Drake T.M., et al. Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. Nephrol Dial Transplant. 2022 Jan 25; 37(2): 271–284. https://doi.org/10.1093/ndt/gfab303. PMID: 34661677.</mixed-citation><mixed-citation xml:lang="en">Sullivan M.K., Lees J.S., Drake T.M., et al. Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. Nephrol Dial Transplant. 2022 Jan 25; 37(2): 271–284. https://doi.org/10.1093/ndt/gfab303. PMID: 34661677.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1; 397(10285): 1637–1645. https://doi.org/10.1016/S01406736(21)00676-0. PMID: 33933206.</mixed-citation><mixed-citation xml:lang="en">RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1; 397(10285): 1637–1645. https://doi.org/10.1016/S0140-6736(21)00676-0. PMID: 33933206.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">RECOVERY Collaborative Group, Horby P., Lim W.S., et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021 Feb 25; 384(8): 693–704. https://doi.org/10.1056/NEJMoa2021436. Epub 2020 Jul 17. PMID: 32678530.</mixed-citation><mixed-citation xml:lang="en">RECOVERY Collaborative Group, Horby P., Lim W.S., et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021 Feb 25; 384(8): 693–704. https://doi.org/10.1056/NEJMoa2021436. Epub 2020 Jul 17. PMID: 32678530.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Genovesi S., Rebora P., Occhino G., et al. Atrial fibrillation and clinical outcomes in a cohort of hospitalized patients with SarsCov-2 Infection and Chronic Kidney Disease. J Clin Med. 2021 Sep 11; 10(18): 4108. https://doi.org/10.3390/jcm10184108. PMID: 34575219.</mixed-citation><mixed-citation xml:lang="en">Genovesi S., Rebora P., Occhino G., et al. Atrial fibrillation and clinical outcomes in a cohort of hospitalized patients with Sars- Cov-2 Infection and Chronic Kidney Disease. J Clin Med. 2021 Sep 11; 10(18): 4108. https://doi.org/10.3390/jcm10184108. PMID: 34575219.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Rydyznski Moderbacher C., Ramirez S.I., Dan J.M., et al. Antigen-Specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020 Nov 12; 183(4): 996–1012.e19. Epub 2020 Sep 16. https://doi.org/10.1016/j.cell.2020.09.038. PMID: 33010815.</mixed-citation><mixed-citation xml:lang="en">Rydyznski Moderbacher C., Ramirez S.I., Dan J.M., et al. Antigen-Specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020 Nov 12; 183(4): 996–1012.e19. Epub 2020 Sep 16. https://doi.org/10.1016/j.cell.2020.09.038. PMID: 33010815.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Panigada M., Bottino N., Tagliabue P., et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020 Jul; 18(7): 1738–1742. Epub 2020 Jun 24. https://doi.org/10.1111/jth.14850. PMID: 32302438.</mixed-citation><mixed-citation xml:lang="en">Panigada M., Bottino N., Tagliabue P., et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020 Jul; 18(7): 1738–1742. Epub 2020 Jun 24. https://doi.org/10.1111/jth.14850. PMID: 32302438.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Lukasz A., Hellpap J., Horn R., et al. Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays. Crit Care. 2008; 12(4): R94. Epub 2008 Jul 29. https://doi.org/10.1186/cc6966. PMID: 18664247.</mixed-citation><mixed-citation xml:lang="en">Lukasz A., Hellpap J., Horn R., et al. Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays. Crit Care. 2008; 12(4): R94. Epub 2008 Jul 29. https://doi.org/10.1186/cc6966. PMID: 18664247.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
